About
Nicki Thompson is a UK biotech executive focused on targeted protein degradation and neurodegenerative disease therapeutics. She was publicly identified as CEO of Amphista Therapeutics in 2022 and as CEO of TRIMTECH Therapeutics in June 2026. Her public profile is that of a company builder and biotech operator rather than a fund manager or documented angel investor.
Areas of interest
biotechdrug discoverytargeted protein degradationneurodegenerative diseasecentral nervous system therapeuticsoncologyprotein aggregation biology